X4 Pharmaceuticals (XFOR) Change in Accured Expenses (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Change in Accured Expenses came in at $2.2 million in Q4 2025, down 35.12% YoY from $3.3 million in Q4 2024, and down 35.66% on a QoQ basis from $3.4 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Change in Accured Expenses (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Change in Accured Expenses data on file, last reported at $2.2 million in Q4 2025.
- Quarterly Change in Accured Expenses fell 35.12% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.0 million (down 128.25% YoY) and the FY2025 annual result came in at -$2.0 million, down 128.25% from the prior year.
- Change in Accured Expenses retreated to $2.2 million in Q4 2025, from $3.4 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $4.5 million in Q2 2023 to a low of -$7.8 million in Q1 2025.
- A 5-year average of $520150.0 and a median of $640500.0 in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 2540.3% — and 2025, when it sank 715.66%.
- Tracing XFOR's Change in Accured Expenses over 5 years: stood at -$1.2 million in 2021, then soared by 304.59% to $2.5 million in 2022, then plunged by 261.85% to -$4.0 million in 2023, then jumped by 182.54% to $3.3 million in 2024, then slumped by 35.12% to $2.2 million in 2025.
- The last three Change in Accured Expenses figures came in at $2.2 million (Q4 2025), $3.4 million (Q3 2025), and $227000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.17 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 3.37 Mn |
| Sep 30, 2025 | 3.37 Mn |
| Jun 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Mar 31, 2025 | -7.78 Mn |
| Mar 31, 2025 | -7.78 Mn |
| Dec 31, 2024 | 3.34 Mn |
| Dec 31, 2024 | 3.34 Mn |
| Sep 30, 2024 | -169,000.00 |
| Sep 30, 2024 | -169,000.00 |
| Jun 30, 2024 | 2.74 Mn |
| Jun 30, 2024 | 2.74 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Dec 31, 2023 | -4.04 Mn |
| Dec 31, 2023 | -4.04 Mn |
| Sep 30, 2023 | 627,000.00 |
| Sep 30, 2023 | 627,000.00 |